hVIVO (LON:HVO) Given Hold Rating at Stifel Nicolaus

hVIVO (LON:HVO)‘s stock had its “hold” rating reissued by equities researchers at Stifel Nicolaus in a note issued to investors on Thursday,Digital Look reports. They currently have a GBX 10 price target on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 25.79% from the company’s current price.

Separately, Shore Capital Group reissued a “buy” rating on shares of hVIVO in a research note on Wednesday, April 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of GBX 15.

hVIVO Stock Performance

HVO traded up GBX 0.45 during trading on Thursday, reaching GBX 7.95. 5,297,082 shares of the company were exchanged, compared to its average volume of 3,636,016. hVIVO has a 52 week low of GBX 4.31 and a 52 week high of GBX 18.50. The company has a current ratio of 1.63, a quick ratio of 1.16 and a debt-to-equity ratio of 38.75. The firm has a 50 day moving average of GBX 7.71 and a 200 day moving average of GBX 6.89. The stock has a market cap of £54.73 million, a P/E ratio of -9.14 and a beta of 1.67.

hVIVO (LON:HVO) last announced its quarterly earnings results on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. The firm had revenue of GBX 4,677 million for the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. On average, sell-side analysts forecast that hVIVO will post 1.5492958 EPS for the current fiscal year.

Insider Activity

In other news, insider Brendan Buckley sold 2,017,000 shares of the firm’s stock in a transaction on Friday, April 24th. The stock was sold at an average price of GBX 9, for a total transaction of £181,530. Insiders own 5.24% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.